The Fort Worth Press - Treatment improves cognition in Down Syndrome patients

USD -
AED 3.672897
AFN 68.266085
ALL 93.025461
AMD 389.644872
ANG 1.80769
AOA 911.999407
ARS 997.22659
AUD 1.54802
AWG 1.795
AZN 1.701725
BAM 1.85463
BBD 2.025224
BDT 119.861552
BGN 1.857551
BHD 0.376464
BIF 2962.116543
BMD 1
BND 1.344649
BOB 6.930918
BRL 5.79695
BSD 1.002987
BTN 84.270352
BWP 13.71201
BYN 3.282443
BYR 19600
BZD 2.02181
CAD 1.40785
CDF 2865.00005
CHF 0.887938
CLF 0.035528
CLP 975.269072
CNY 7.2325
CNH 7.23645
COP 4499.075435
CRC 510.454696
CUC 1
CUP 26.5
CVE 104.561187
CZK 23.976402
DJF 178.606989
DKK 7.078013
DOP 60.43336
DZD 133.184771
EGP 49.296856
ERN 15
ETB 121.465364
EUR 0.94835
FJD 2.27595
FKP 0.789317
GBP 0.792519
GEL 2.735035
GGP 0.789317
GHS 16.022948
GIP 0.789317
GMD 71.000178
GNF 8643.497226
GTQ 7.746432
GYD 209.748234
HKD 7.785502
HNL 25.330236
HRK 7.133259
HTG 131.85719
HUF 387.387031
IDR 15898.3
ILS 3.749305
IMP 0.789317
INR 84.47775
IQD 1313.925371
IRR 42092.506597
ISK 137.650409
JEP 0.789317
JMD 159.290693
JOD 0.709098
JPY 154.314969
KES 129.894268
KGS 86.499375
KHR 4051.965293
KMF 466.574996
KPW 899.999621
KRW 1395.925003
KWD 0.30754
KYD 0.835902
KZT 498.449576
LAK 22039.732587
LBP 89819.638708
LKR 293.025461
LRD 184.552653
LSL 18.247689
LTL 2.95274
LVL 0.60489
LYD 4.898772
MAD 9.999526
MDL 18.224835
MGA 4665.497131
MKD 58.423024
MMK 3247.960992
MNT 3397.999946
MOP 8.042767
MRU 40.039827
MUR 47.210137
MVR 15.449644
MWK 1739.225262
MXN 20.359042
MYR 4.4705
MZN 63.901154
NAD 18.247689
NGN 1665.820256
NIO 36.906737
NOK 11.107098
NPR 134.832867
NZD 1.729727
OMR 0.384524
PAB 1.002987
PEN 3.80769
PGK 4.033
PHP 58.731498
PKR 278.485894
PLN 4.10208
PYG 7826.086957
QAR 3.656441
RON 4.72391
RSD 110.944953
RUB 99.872647
RWF 1377.554407
SAR 3.756134
SBD 8.390419
SCR 13.840165
SDG 601.506089
SEK 10.98415
SGD 1.343696
SHP 0.789317
SLE 22.581281
SLL 20969.504736
SOS 573.230288
SRD 35.315499
STD 20697.981008
SVC 8.776255
SYP 2512.529858
SZL 18.240956
THB 34.905979
TJS 10.692144
TMT 3.51
TND 3.164478
TOP 2.3421
TRY 34.44532
TTD 6.810488
TWD 32.476797
TZS 2667.962638
UAH 41.429899
UGX 3681.191029
UYU 43.042056
UZS 12838.651558
VES 45.732111
VND 25390
VUV 118.722009
WST 2.791591
XAF 622.025509
XAG 0.033067
XAU 0.00039
XCD 2.70255
XDR 0.755583
XOF 622.025509
XPF 113.090892
YER 249.875023
ZAR 18.189595
ZMK 9001.211502
ZMW 27.537812
ZWL 321.999592
  • SCS

    -0.0400

    13.23

    -0.3%

  • NGG

    0.3800

    62.75

    +0.61%

  • BTI

    0.9000

    36.39

    +2.47%

  • GSK

    -0.6509

    33.35

    -1.95%

  • RBGPF

    61.8400

    61.84

    +100%

  • RYCEF

    0.0400

    6.82

    +0.59%

  • RIO

    0.5500

    60.98

    +0.9%

  • CMSC

    0.0200

    24.57

    +0.08%

  • AZN

    -1.8100

    63.23

    -2.86%

  • BP

    -0.0700

    28.98

    -0.24%

  • BCE

    -0.0200

    26.82

    -0.07%

  • BCC

    -0.2600

    140.09

    -0.19%

  • VOD

    0.0900

    8.77

    +1.03%

  • CMSD

    0.0822

    24.44

    +0.34%

  • RELX

    -1.5000

    44.45

    -3.37%

  • JRI

    0.0235

    13.1

    +0.18%

Treatment improves cognition in Down Syndrome patients
Treatment improves cognition in Down Syndrome patients / Photo: © AFP/File

Treatment improves cognition in Down Syndrome patients

A new hormone treatment improved the cognitive function of six men with Down Syndrome by 10-30 percent, scientists said Thursday, adding the "promising" results may raise hopes of improving patients' quality of life.

Text size:

However the scientists emphasised the small study did not point towards a cure for the cognitive disorders of people with Down Syndrome and that far more research is needed.

"The experiment is very satisfactory, even if we remain cautious," said Nelly Pitteloud of Switzerland's Lausanne University Hospital and co-author of a new study in the journal Science.

Down Syndrome is the most common genetic form of intellectual disability, occurring in around one in 1,000 people, according to the World Health Organization.

Yet previous research has failed to significantly improve cognition when applied to people with the condition, which is why the latest findings are "particularly important", the study said.

Recent discoveries have suggested that how the gonadotropin-releasing hormone (GnRH) is produced in the brain can affect cognitive functioning such as memory, language and learning.

GnRH hormones regulate how much testosterone and estrogen is produced and increased levels of it help spur puberty.

"We wondered if this hormone could play any role in establishing the symptoms of people with Down Syndrome," said Vincent Prevot, study co-author and head of neuroscience research at France's INSERM institute.

- Mice research -

The team first established that five strands of microRNA regulating the production of GnRH were dysfunctional in mice specifically engineered for Down Syndrome research.

They then demonstrated that cognitive deficiencies -- as well as loss of smell, a common symptom of Down Syndrome -- were linked to dysfunctioning GnRH secretion in the mice.

The team then gave the mice a GnRH medication used to treat low testosterone and delayed puberty in humans, finding that it restored some cognitive function and sense of smell.

A pilot study was conducted in Switzerland involving seven men with Down Syndrome aged 20 to 50.

They each received the treatment through their arm every two hours over a period of six months, with the drug delivered in pulses to mimic the hormone's frequency in people without Down Syndrome.

Cognition and smell tests were carried out during the treatment, as were MRI scans.

Six of the seven men showed improvement in cognition with no significant side effects -- however none showed a change in their sense of smell.

"We have seen an improvement of between 10-30 percent in cognitive functions, in particular with visuospatial function, three-dimensional representation, understanding of instructions as well as attention," Pitteloud said.

The patients were asked to draw a simple 3D bed at several stages throughout the therapy. Many struggled at the beginning but by the end the efforts were noticeably better.

- 'Improve quality of life' -

The authors acknowledged some limitations of the study, including its size and that the choice of patients was "pushed by their parents".

"The clinical trial only focused on seven male patients -- we still have a lot of work to do to prove the effectiveness of GnRH treatment for Down Syndrome," Pitteloud said.

A larger study involving a placebo and 50 to 60 patients, a third of them women, is expected to begin in the coming months.

"We are not going to cure the cognitive disorders of people with Down Syndrome, but the improvement seen in our results already seems fundamental enough to hope to improve their quality of life," Pitteloud said.

Fabian Fernandez, an expert in cognition and Down Syndrome at the University of Arizona who was not involved in the research, hailed the "tour de force study".

He told AFP that while it is "difficult to envision" how such an intensive treatment could be used for young people, it might be better suited to delay the Alzheimer's disease-related dementia suffered by many adults with Down Syndrome.

It was also difficult to predict how such an improvement could impact the lives of people with the condition, he said.

"For some, it could be significant, however, as it would enable them to be more independent with daily living activities such as maintaining and enjoying hobbies, finding belongings, using appliances in the home, and travelling alone."

P.McDonald--TFWP